Taiwan Bio Therapeutics Co., Ltd.

As of June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. carries a market capitalization of 2.81B, placing it among publicly traded companies globally. Its enterprise value stands at 2.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. has 84.90M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 26.41, and the price-to-book ratio stands at 3.13.

These figures are as of June 30, 2025. The EV/Sales ratio of 25.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.61B versus a market cap of 2.81B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. maintains a current ratio of 8.15, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.66, indicating elevated leverage, while an interest coverage ratio of -45.87 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. posted a negative return on equity (ROE) of -45.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.51, reflecting losses generated across the asset base. The company generates approximately 1.40M in revenue per employee across its workforce of 73.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.97 indicates how many times Taiwan Bio Therapeutics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. recorded 25,000.00 in income tax expense. The company reported a pretax loss of -406.27M and -406.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Taiwan Bio Therapeutics Co., Ltd.'s stock has declined approximately 3.82% over the past 52 weeks. The 50-day moving average sits at 26.08, while the 200-day moving average is 26.97.

Over the twelve months ended June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. generated 102.40M in revenue and converted that into -406.29M in net income, yielding earnings per share of -4.97. EBITDA reached -281.32M, while operating income came in at -394.30M.

As of June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. holds 529.60M in cash and equivalents against 329.48M in total debt, resulting in a net debt position of -529.60M. Total book value stands at 898.80M, with working capital of 545.28M providing operational flexibility.

Taiwan Bio Therapeutics Co., Ltd. produced -265.12M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -35.28M in capital expenditures, free cash flow totaled -300.40M - equivalent to -3.67 per share.

Over the twelve months ended June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. posted a gross margin of 56.94, reflecting its pricing power and cost economics. The operating margin of -385.07 and net profit margin of -396.79 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -11.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.60, meaning Taiwan Bio Therapeutics Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Taiwan Bio Therapeutics Co., Ltd.'s most recent stock split took place on December 17, 2025 with a 201:202 split ratio.

As of June 30, 2025, Taiwan Bio Therapeutics Co., Ltd. has an Altman Z-Score of 3.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.